HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationship among serum 25-hydroxyvitamin D, fibrosis stage, genetic susceptibility, and risk of severe liver disease.

AbstractOBJECTIVES:
The prospective association between vitamin D and new-onset severe liver disease is still uncertain. The aim of this study was to assess the association of serum 25-hydroxyvitamin D (25(OH)D) with new-onset severe liver disease and to evaluate whether fibrosis stage, as assessed by the fibrosis- 4 (FIB-4) scores and genetic risk for liver cirrhosis may modify this association.
METHODS:
The study included 439 807 participants without liver diseases at baseline from the UK Biobank. Serum 25(OH)D concentrations were measured using the chemiluminescent immunoassay method. The primary outcome was new-onset severe liver disease, a composite definition of compensated or decompensated liver cirrhosis, liver failure, hepatocellular carcinoma, and liver-related death.
RESULTS:
During a median follow-up of 12 y, 4510 participants developed new-onset severe liver disease. Overall, there was an inverse association of serum 25(OH)D with new-onset severe liver disease (per SD increment, adjusted hazard ratio [HR], 0.87; 95% confidence interval, 0.84-0.91). Similarly, serum 25(OH)D (per SD increment) was significantly and inversely associated with new-onset compensated cirrhosis, decompensated cirrhosis, liver failure, and liver-related death, respectively, with HRs ranging from 0.75 to 0.87. No significant association was found for hepatocellular carcinoma. Furthermore, there was a stronger inverse association between serum 25(OH)D and severe liver disease among those with a higher FIB-4 score (≥2.67, 1.3 to <2.67, and <1.3; Pinteraction < 0.001). However, the genetic risks for liver cirrhosis, calculated using 12 related single nucleotide polymorphisms, did not significantly modify the association between serum 25(OH)D and severe liver disease (Pinteraction = 0.216).
CONCLUSIONS:
Lower serum 25(OH)D concentrations were significantly associated with a greater risk for new-onset severe liver disease, especially in participants with higher FIB-4 scores.
AuthorsChun Zhou, Yanjun Zhang, Ziliang Ye, Panpan He, Yuanyuan Zhang, Xiaoqin Gan, Sisi Yang, Mengyi Liu, Qimeng Wu, Xianhui Qin
JournalNutrition (Burbank, Los Angeles County, Calif.) (Nutrition) Vol. 119 Pg. 112320 (Mar 2024) ISSN: 1873-1244 [Electronic] United States
PMID38185094 (Publication Type: Journal Article)
CopyrightCopyright © 2023 Elsevier Inc. All rights reserved.
Chemical References
  • 25-hydroxyvitamin D
  • Vitamin D
  • Calcifediol
Topics
  • Humans
  • Carcinoma, Hepatocellular (genetics, complications)
  • Vitamin D Deficiency
  • Vitamin D (analogs & derivatives)
  • Calcifediol
  • Liver Cirrhosis (genetics)
  • Liver Failure (complications)
  • Liver Neoplasms (genetics, complications)
  • Genetic Predisposition to Disease

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: